4.6 Article

Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors

Juan Carlos Rodriguez-Duque et al.

Summary: This study investigated the prevalence and risk factors of metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). The results showed that the prevalence of MAFLD and liver fibrosis was significantly higher in IBD patients compared to the general population, independent of traditional metabolic risk factors. This study is important for understanding the liver health of IBD patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East Region

Janus Ong et al.

CLINICS IN LIVER DISEASE (2023)

Article Gastroenterology & Hepatology

Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease

Hye Kyung Hyun et al.

Summary: This study investigated the effects of nonalcoholic fatty liver disease (NAFLD) on the outcome of inflammatory bowel disease (IBD) patients. The results showed that the presence of NAFLD may increase the risk of clinical relapse in patients with IBD. Additionally, the study found that hepatic steatosis was significantly associated with increased risks of clinical relapse in patients with ulcerative colitis and Crohn's disease, while fibrotic burden in the liver was not.

GUT AND LIVER (2023)

Article Gastroenterology & Hepatology

Real-world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan

Hsu-Heng Yen et al.

Summary: This study retrospectively reviewed the treatment outcomes of adalimumab therapy in Taiwanese patients with ulcerative colitis. The majority of patients who responded to adalimumab experienced relapse after the limited duration of therapy.

ADVANCES IN DIGESTIVE MEDICINE (2023)

Article Gastroenterology & Hepatology

Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease

Mohammad Zamani et al.

Summary: One-third of patients with inflammatory bowel disease (IBD) experience non-alcoholic fatty liver disease (NAFLD) worldwide. The risk of NAFLD was two times higher in IBD patients compared to healthy subjects.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Article Medicine, General & Internal

Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease

Claudia Veltkamp et al.

Summary: IBD patients often develop liver problems such as hepatic steatosis and fibrosis. Factors associated with hepatic steatosis include age, BMI, disease duration, and specific serum activities. Hepatic fibrosis is more common in CD patients.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Health Care Sciences & Services

Machine-Learning Algorithm for Predicting Fatty Liver Disease in a Taiwanese Population

Yang-Yuan Chen et al.

Summary: This study used machine-learning algorithms to predict fatty liver disease in Taiwanese subjects and compared the performance with the fatty liver index. The xgBoost model showed the best performance in predicting fatty liver disease, and body mass index was identified as the most important predictor.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Article Gastroenterology & Hepatology

Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare

Gabrielle Ritaccio et al.

Summary: This study aimed to examine the prevalence of NAFLD and trends in NAFLD-associated fibrosis in IBD patients. The results showed that most IBD patients with NAFLD had stable liver disease over 5 years, with only a small percentage experiencing worsening or improvement in NFS category.

DIGESTIVE DISEASES AND SCIENCES (2021)

Article Multidisciplinary Sciences

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study

Hsu-Heng Yen et al.

Summary: The prevalence of NAFLD in Taiwanese IBD patients was 29.6%, lower than in the Western population. Higher BMI and older age were associated with NAFLD in this study.

PLOS ONE (2021)

Article Gastroenterology & Hepatology

Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography

Chiara Saroli Palumbo et al.

INFLAMMATORY BOWEL DISEASES (2019)

Article Gastroenterology & Hepatology

Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history

Salvatore Magri et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

Review Immunology

A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease

Qingdong Guan

JOURNAL OF IMMUNOLOGY RESEARCH (2019)

Article Gastroenterology & Hepatology

Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis

Kamolyut Lapumnuaypol et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2018)

Article Gastroenterology & Hepatology

Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors

Mariabeatrice Principi et al.

INFLAMMATORY BOWEL DISEASES (2018)

Review Gastroenterology & Hepatology

Noninvasive biomarkers in NAFLD and NASH - current progress and future promise

Vincent Wai-Sun Wong et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)

Article Gastroenterology & Hepatology

Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study

Shintaro Sagami et al.

HEPATOLOGY RESEARCH (2017)

Article Gastroenterology & Hepatology

Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease

Leonard Haas et al.

DIGESTIVE DISEASES AND SCIENCES (2017)

Article Gastroenterology & Hepatology

Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease

Talat Bessissow et al.

INFLAMMATORY BOWEL DISEASES (2016)

Article Gastroenterology & Hepatology

Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease

Avegail Flores et al.

DIGESTIVE DISEASES AND SCIENCES (2015)

Review Endocrinology & Metabolism

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

Hannele Yki-Jarvinen

LANCET DIABETES & ENDOCRINOLOGY (2014)

Article Gastroenterology & Hepatology

Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease

Achuthan Sourianarayanane et al.

Journal of Crohns & Colitis (2012)

Article Gastroenterology & Hepatology

Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver Disease

Vincent Wai-Sun Wong et al.

HEPATOLOGY (2010)

Article Gastroenterology & Hepatology

Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study

Srinivasan Dasarathy et al.

JOURNAL OF HEPATOLOGY (2009)

Article Gastroenterology & Hepatology

The natural history of nonalcoholic fatty liver disease: A population-based cohort study

LA Adams et al.

GASTROENTEROLOGY (2005)